









Markets
/
Stocks
/
nasdaq-rvmd
/

Revolution Medicines Inc

RVMD

93.510USD

-0.780-0.83%

Market hours （ET）Quotes delayed by 15 min

4.95BMarket Cap

LossP/E TTM



Revolution Medicines Inc

93.510

-0.780-0.83%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Revolution Medicines Inc

Currency: USD Updated: 2026-03-26

Key Insights

Revolution Medicines Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 66 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 134.16.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Revolution Medicines Inc's Score

Industry at a Glance

Industry Ranking

66 / 391

Overall Ranking

168 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Revolution Medicines Inc Highlights

StrengthsRisks

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -15.67, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 202.03M shares, decreasing 1.47% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 656.00 shares of this stock.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

134.158

Target Price

+40.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of Revolution Medicines Inc is 5.20, ranking 375 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.20

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.73

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Revolution Medicines Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of Revolution Medicines Inc is 6.63, ranking 241 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -15.67, which is -64.10% below the recent high of -5.62 and -51.60% above the recent low of -23.75.

Score

Industry at a Glance

Previous score

6.63

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 66/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of Revolution Medicines Inc is 8.86, ranking 43 out of 391 in the Biotechnology & Medical Research industry. The average price target is 76.50, with a high of 99.00 and a low of 70.00.

Score

Industry at a Glance

Previous score

8.86

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

134.158

Target Price

+40.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Revolution Medicines Inc

RVMD

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of Revolution Medicines Inc is 6.68, ranking 206 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 100.82 and the support level at 89.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.78

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.109

Sell

RSI(14)

38.182

Neutral

STOCH(KDJ)(9,3,3)

15.624

Sell

ATR(14)

3.353

High Vlolatility

CCI(14)

-158.617

Sell

Williams %R

92.900

Oversold

TRIX(12,20)

-0.196

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

95.086

Sell

MA10

96.582

Sell

MA20

98.125

Sell

MA50

101.481

Sell

MA100

89.474

Buy

MA200

65.660

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Revolution Medicines Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 104.50%, representing a quarter-over-quarter increase of 4.14%. The largest institutional shareholder is The Vanguard, holding a total of 16.69M shares, representing 8.42% of shares outstanding, with 5.41% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

15.63M

-0.63%

Farallon Capital Management, L.L.C.

14.63M

+2.09%

Janus Henderson Investors

11.36M

+7.23%

Baker Bros. Advisors LP

9.46M

+0.97%

Fidelity Management & Research Company LLC

9.40M

+12.93%

BlackRock Institutional Trust Company, N.A.

7.49M

-4.49%

Nextech Invest, Ltd.

7.60M

Wellington Management Company, LLP

9.81M

-4.35%

Paradigm BioCapital Advisors LP

6.22M

+2.13%

Bellevue Asset Management AG

5.57M

+21.72%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Revolution Medicines Inc is 6.55, ranking 23 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Revolution Medicines Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.